menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Poster Pearl: When to Screen Patients with Discordant CRC Results

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    When a patient receives a positive result from their multi-target stool DNA test but then a negative result from their colonoscopy, this creates a unique challenge and even some controversy for healthcare professionals in terms of when the next colorectal cancer (CRC) screening test should be administered. That’s why a recent poster presented at the 2023 American College of Gastroenterology Annual Scientific Meeting explored what’s currently being done in clinical practice and found that most patients with discordant results received a follow-up CRC screening test within 3 to 5 years. Dive further into the study’s findings and implications with Dr. Charles Turck and Dr. Nicholas Talabiska, a PGY-3 internal medicine resident at Temple University Hospital in Philadelphia. 

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    When a patient receives a positive result from their multi-target stool DNA test but then a negative result from their colonoscopy, this creates a unique challenge and even some controversy for healthcare professionals in terms of when the next colorectal cancer (CRC) screening test should be administered. That’s why a recent poster presented at the 2023 American College of Gastroenterology Annual Scientific Meeting explored what’s currently being done in clinical practice and found that most patients with discordant results received a follow-up CRC screening test within 3 to 5 years. Dive further into the study’s findings and implications with Dr. Charles Turck and Dr. Nicholas Talabiska, a PGY-3 internal medicine resident at Temple University Hospital in Philadelphia. 

Facebook Comments

Schedule22 Jun 2024